Subcutaneous Immunoglobulin (SCIG) injection

Form: Injection

Strength: 20%, 10 mL/ampoule

Reference Brands: Hizentra, Cuvitru, Vivaglobulin(US)

Category: Plasma Products

Subcutaneous Immunoglobulin (SCIG), marketed as Hizentra, Cuvitru, and Vivaglobulin, is approved in the US by the FDA and in the EU via EMA for primary immunodeficiency and autoimmune diseases. Regulatory approval requires a comprehensive dossier including clinical efficacy, safety data, manufacturing quality, and pharmacovigilance plans. In the US, FDA review involves detailed assessment of clinical trials and manufacturing standards, while the EMA ensures compliance with regional quality and safety requirements. For expert guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Ensuring compliance is crucial for the safe, effective, and timely approval of SCIG products worldwide, supporting better patient outcomes.